Mineralys Therapeutics (MLYS) Projected to Post Earnings on Wednesday

Key Points

• Mineralys Therapeutics is expected to post Q1 2026 results after the market close on Wednesday, May 6, 2026 at 4:30 PM ET, with analysts forecasting EPS of ($0.51); the company beat estimates last quarter, reporting ($0.40) vs. ($0.57) expected.
• Shares have a market cap of $2.41 billion and a one‑year range of $12.59–$47.65, and analysts hold a consensus Moderate Buy rating with a $49.14 target (7 Buys, 1 Hold, 1 Sell).
• Insiders sold 162,291 shares worth $4.34M over the last three months (insiders own 18.94%), while institutional investors hold 84.46% of the company’s stock.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) is expected to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Mineralys Therapeutics to post earnings of ($0.51) per share for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last released its earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. On average, analysts expect Mineralys Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $29.26 on Friday. The firm has a market capitalization of $2.41 billion, a price-to-earnings ratio of -12.35 and a beta of 0.49. Mineralys Therapeutics has a one year low of $12.59 and a one year high of $47.65. The company has a 50 day moving average price of $27.11 and a 200 day moving average price of $33.56.

Analyst Ratings Changes

Several analysts have recently issued reports on MLYS shares. Bank of America boosted their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a "buy" rating in a research note on Friday, March 13th. TD Cowen started coverage on Mineralys Therapeutics in a report on Monday. They issued a "buy" rating on the stock. Jefferies Financial Group reissued a "hold" rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Tuesday, April 21st. Finally, Wall Street Zen upgraded Mineralys Therapeutics from a "sell" rating to a "hold" rating in a report on Sunday, March 15th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Mineralys Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.14.

Insider Buying and Selling at Mineralys Therapeutics

In related news, Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $25.00, for a total transaction of $75,000.00. Following the transaction, the director owned 6,200 shares in the company, valued at approximately $155,000. The trade was a 32.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 6,348 shares of the company's stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $27.66, for a total transaction of $175,585.68. Following the sale, the insider directly owned 69,792 shares of the company's stock, valued at approximately $1,930,446.72. This trade represents a 8.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 162,291 shares of company stock worth $4,336,414 over the last three months. 18.94% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada grew its stake in shares of Mineralys Therapeutics by 262.3% in the fourth quarter. Royal Bank of Canada now owns 1,529 shares of the company's stock valued at $56,000 after buying an additional 1,107 shares in the last quarter. Russell Investments Group Ltd. lifted its position in Mineralys Therapeutics by 14,091.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 3,264 shares of the company's stock worth $124,000 after acquiring an additional 3,241 shares in the last quarter. Victory Capital Management Inc. acquired a new position in Mineralys Therapeutics during the 3rd quarter worth approximately $216,000. FORA Capital LLC purchased a new position in Mineralys Therapeutics in the 3rd quarter worth approximately $240,000. Finally, Persistent Asset Partners Ltd purchased a new position in Mineralys Therapeutics in the 4th quarter worth approximately $269,000. Institutional investors and hedge funds own 84.46% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.